Opinion
Video
Review of the COMMANDS Trial
Author(s):
The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.
- Dr Garcia-Manero: Briefly summarize the COMMANDS trial, evaluating luspatercept in patients with lower-risk MDS (Platzbecker U et al. Lancet Onco 2023).
- Briefly comment on the study design, patient population, and primary/secondary endpoints.
Related Videos
Related Content
